Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole transcriptome analysis identifies differentially regulated networks during the proliferation inhibition and megakaryocytic differentiation of AML cell induced by 3,8-Di-O-methylellagic acid 2-O-glucoside (DMAG) derived from Sanguisorba offcinalis L.

ABSTRACT: Whole transcriptome analysis identifies differentially regulated networks during the proliferation inhibition and megakaryocytic differentiation of AML cell induced by 3,8-Di-O-methylellagic acid 2-O-glucoside (DMAG) derived from Sanguisorba offcinalis L.

PROVIDER: PRJNA598846 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10822923_1.fastq.gz	Fastqsanger.gz
	SRR10822923_2.fastq.gz	Fastqsanger.gz
	SRR10822924_1.fastq.gz	Fastqsanger.gz
	SRR10822924_2.fastq.gz	Fastqsanger.gz
	SRR10822925_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Whole transcriptome analysis identifies differentially regulated networks during the proliferation inhibition and megakaryocytic differentiation of AML cell induced by 3,8-Di-O-methylellagic acid 2-O-glucoside (DMAG) derived from Sanguisorba offcinalis L.

Project description:We identified the expression profiles of lncRNA, mRNA, miRNA and circRNA by whole-transcriptome sequencing and constructed co-expression network to elucidate the potential mechanisms of 3,8-Di-O-methylellagic acid 2-O-glucoside in anti-AML eﬀect

2022-01-01 | GSE142994 | GEO

17-DMAG treatment in primary CLL B cells

Project description:We used microarrays to analyze gene expression following treatment of leukemic B cells with the Hsp90 inhibitor 17-DMAG. Gene expression profiling reveals the role of SOCS3 in cytokine signaling in CLL Primary cells from CLL patients were isolated and treated in vitro with 17-DMAG. Cells were collected for viability, gene expression analysis and cell signaling and migration assays.

2016-07-01 | E-GEOD-76546 | biostudies-arrayexpress

17-DMAG treatment in primary CLL B cells

2016-07-01 | GSE76546 | GEO

Identification of 17-DMAG as a novel KDM4B inhibitor for combination therapy [RNA-seq]

Project description:Histone lysine demethylases (KDMs) are emerging as therapeutic targets in cancer. Development of potent KDM inhibitors may provide additional options for epigenomics-oriented therapies. Using a Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) functional demethylation assay, in combination with a high-content immunofluorescence imaging phenotypic screen, Matrix-Assisted Laser Desorption/Ionization- Fourier Transform Ion Cyclotron Resonance mass spectrometry (MALDI-FTICR MS) and Amplified Luminescent Proximity Homogeneous Assay (ALPHA), we identified geldanamycin, an inhibitor of heat shock protein 90 (Hsp90), as a novel inhibitor of JmjC-domain containing demethylases such as KDM4B. We further found that geldanamycin can destabilize the PAX3-FOXO1 fusion oncoprotein, an Hsp90 client, which is a driver of clinically unfavorable alveolar rhabdomyosarcoma (aRMS). We then hypothesized that dual inhibition of PAX3-FOXO1 and epigenetic modifiers of aRMS would have synergistic antitumor activity. We repurposed the geldanamycin analog 17-DMAG to target aRMS and found that 17-DMAG significantly delays tumor growth , extends survival in xenograft mouse models, and inhibits expression of PAX3-FOXO1 targets and multiple oncogenic pathways including MYC, E2F and NOTCH. In addition, the combination of 17-DMAG with conventional chemotherapy or the bromodomain inhibitor JQ1 significantly enhances therapeutic efficacy. In summary, we have identified geldanamycin and 17-DMAG as dual KDM/Hsp90 inhibitors and 17-DMAG is efficacious against PAX3-FOXO1-driven rhabdomyosarcoma.

2020-12-21 | GSE151514 | GEO

Expression data from Cyanidine (Cyanidine 3-glucoside)-treated human amnion epithelial cells (hAECs)

Project description:Gene expression profiling of the effect of Cyanidine 3 glucoside treatment in hAECs.

2020-04-17 | GSE148776 | GEO

Identification of 17-DMAG as a novel KDM4B inhibitor for combination therapy [ChIP-seq]

Project description:Histone demethylases such as KDM4B play critical roles in oncogenic pathophysiology and, therefore may be effective targets for anticancer therapy. Using a TR-FRET demethylation screen assay, in combination with multiple orthogonal validation approaches, we identified geldanamycin and its analog 17-DMAG as novel KDM4B inhibitors. In addition, we found that these Hsp90 inhibitors effect increased degradation of the alveolar rhabdomyosarcoma (aRMS) driver oncoprotein PAX3-FOXO1 and induce the H3K9me3 and H3K36me3 at genomic loci of PAX3-FOXO1 targets. We found that as monotherapy 17-DMAG significantly inhibits expression of PAX3-FOXO1 target genes and multiple oncogenic pathways, induces a muscle differentiation signature, delays tumor growth and extends survival in aRMS xenograft mouse models. The combination of 17-DMAG with conventional chemotherapy significantly enhances therapeutic efficacy, indicating that targeting KDM4B in combination with chemotherapy may serve as a novel therapy to PAX3-FOXO1-positive aRMS.

2020-12-22 | GSE151493 | GEO

SON inhibits megakaryocytic differentiation via repressing the megakaryocytic gene expression program in acute megakaryoblastic leukemia

Project description:A high incidence of acute megakaryoblastic leukemia (AMKL) in Down syndrome patients implies that chromosome 21 genes have a pivotal role in AMKL development, but the functional contribution of individual genes remains elusive. Here, we report that SON, a chromosome 21-encoded DNA- and RNA-binding protein, inhibits megakaryocytic differentiation by suppressing RUNX1 and the megakaryocytic gene expression program. As megakaryocytic progenitors differentiate, SON expression is drastically reduced, with mature megakaryocytes having the lowest levels. In contrast, AMKL cells express an aberrantly high level of SON, and knockdown of SON induced the onset of megakaryocytic differentiation in AMKL cell lines. Genome-wide transcriptome analyses revealed that SON knockdown turns on the expression of pro-megakaryocytic genes while reducing erythroid gene expression. Mechanistically, SON represses RUNX1 expression by directly binding to the proximal promoter and two enhancer regions, the known +23 kb enhancer and the novel +139 kb enhancer, at the RUNX1 locus to suppress H3K4 methylation. In addition, SON represses the expression of the AP-1 complex subunits JUN, JUNB and FOSB which are required for late megakaryocytic gene expression. Our findings define SON as a negative regulator of RUNX1 and megakaryocytic differentiation, implicating SON overexpression in impaired differentiation during AMKL development.

2020-09-01 | GSE157178 | GEO

Effects of 17-DMAG treatment on transcription in 4T1 cells populations resistant and non-resistant to 17-DMAG

Project description:Effects of 17-DMAG treatment on transcription in 4T1 cells populations resistant and non-resistant to 17-DMAG

| PRJNA896604 | ENA

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Project description:RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with an advanced solid tumor or lymphoma.

| 2011214 | ecrin-mdr-crc

Mangrovimonas sp. DI 80 strain:DI 80 | isolate:DI 80 | breed:prokaryotic | cultivar:Shiva.S

Project description:Mangrovimonas sp. DI 80 strain:DI 80 | isolate:DI 80 | breed:prokaryotic | cultivar:Shiva.S Genome sequencing and assembly

| PRJNA348568 | ENA